Mazdutide vs Tirzepatide: A Comparative Analysis for Weight Loss

What is Tirzepatide

Tirzepatide is an innovative injectable medication developed by Eli Lilly, approved for managing type 2 diabetes (as Mounjaro) and chronic weight loss (as Zepbound). It’s a first-in-class dual agonist targeting both GLP-1 and GIP receptors, setting it apart from single-receptor peptides like semaglutide. [1]

Its mechanism promotes insulin secretion, slows gastric emptying, and reduces appetite, leading to notable improvements in glycaemic control and body weight reduction. Clinical trials, including the SURMOUNT-5 study, demonstrate tirzepatide’s ability to achieve 13.7-20.2% weight loss in individuals with obesity but without type 2 diabetes, outperforming other GLP-1 receptor agonists in direct comparisons. [2]

Serious risks, though rare, include pancreatitis, gallbladder issues, and a potential for thyroid tumors. Administered weekly, doses range from 2.5 mg to 15 mg.

What Is Mazdutide

Mazdutide (also known as IBI362 or LY3305677) is a groundbreaking peptide developed by Innovent Biologics, designed for the treatment of obesity and type 2 diabetes. It is a novel dual agonist that simultaneously targets glucagon-like peptide-1 (GLP-1) and glucagon receptors (GCGR), distinguishing it from other incretin-based peptides like semaglutide or tirzepatide. This dual mechanism promotes weight loss by increasing energy expenditure through glucagon receptor activation while enhancing insulin secretion and suppressing appetite via GLP-1 receptor activation. [3]

In phase II clinical trials, such as those reported in peer-reviewed journals, mazdutide demonstrated significant efficacy, achieving 10–14% body weight reduction in adults with obesity over 32 to 48 weeks. For type 2 diabetes, it improved glycemic control, reducing HbA1c levels effectively. The safety profile is favorable, with common side effects including mild to moderate gastrointestinal issues like nausea and diarrhea, and a low rate of discontinuation due to adverse events. Administered as a once-weekly subcutaneous injection, mazdutide shows promise as a long-term treatment option [3] [4]

Mazdutide vs Tirzepatide

Type 2 Diabetes

Both mazdutide and tirzepatide address the growing challenge of type 2 diabetes, a condition affecting millions globally, characterized by insulin resistance and increased blood sugar. Effective diabetes management requires therapies that not only lower blood glucose but also tackle associated complications like obesity. Mazdutide and tirzepatide both demonstrate significant improvements in HbA1c, fasting plasma glucose, and insulin sensitivity, making them valuable tools for patients with type 2 diabetes. However, their approaches differ. [3]

Mazdutide stands out due to its unique dual agonism of GLP-1 and glucagon receptors, which not only enhances insulin secretion and suppresses appetite but also increases energy expenditure, eventually leading to weight loss. [3]

On the other hand, Tirzepatide distinguishes itself with dual GLP-1 and GIP receptor agonism, achieving HbA1c reductions of up to 2.4% and weight loss of up to 8.8 kg at 15 mg in SURPASS trials. Its GIP component enhances insulin sensitivity, making it highly effective for glycemic control. [4]

Obesity and Weight Loss Treatment

Obesity, defined as excess body fat that impairs health, drives demand for effective weight management solutions. Mazdutide and tirzepatide both target weight loss as a primary outcome, addressing the global obesity epidemic impacting 1 in 8 people. Weight loss not only improves physical health but also reduces the risks of type 2 diabetes, cardiovascular disease, and other comorbidities.

Clinical trials reveal tirzepatide’s edge in achieving higher weight loss percentages, often exceeding 20% in non-diabetic obesity patients, while mazdutide shows great results, with up to 14% weight reduction in phase II studies. Both medications slow gastric emptying and reduce appetite, but their receptor targets create nuanced differences in outcomes. [2] [3]

Comparing Clinical Trials

A randomized trial compared tirzepatide (10 mg or 15 mg) to semaglutide (1.7 mg or 2.4 mg) in adults with obesity but without type 2 diabetes over 72 weeks, showing tirzepatide’s superior weight loss and waist circumference reduction. [2]

Mazdutide’s phase II trial in adults with obesity or excess weight showed approximately 10-14% weight loss at 4 mg and 6 mg doses over 32 to 48 weeks, with ongoing phase III trials investigating higher doses and effects on type 2 diabetes. [3]

While both medications show promise, tirzepatide’s more extensive phase III data currently provides a deeper evidence base compared to mazdutide’s ongoing trials.

Mechanism of Action

Mazdutide and tirzepatide belong to the class of GLP-1 receptor agonists.

Tirzepatide’s dual GLP-1 and GIP receptor activation enhances insulin secretion and appetite suppression, leading to significant weight loss and glycaemic control. [1]

Mazdutide, by contrast, pairs GLP-1 with glucagon receptor activation, which boosts energy expenditure, offering a complementary approach to weight reduction. This distinction makes mazdutide a unique peptide, potentially filling gaps for patients who respond less to GIP-based therapies. [3]

Safety and Risks

Safety remains an important consideration for any medication. Both mazdutide and tirzepatide exhibit gastrointestinal side effects, such as nausea, diarrhea, and vomiting, which are common among GLP-1 receptor agonists. [5]

• Mazdutide’s phase II study reported these adverse events as mild to moderate, with minimal treatment discontinuation, suggesting good tolerability.
• Tirzepatide’s safety profile, backed by larger trials, shows similar side effects but with proven real-world tolerability.

Both drugs aim to minimize risks while maximizing benefits for weight and diabetes management, with ongoing studies refining their long-term safety profiles.

Accessibility and Cost

Tirzepatide, known by the brand name Mounjaro, is already on the market and approved for use, with further studies underway to explore its potential in weight loss. In comparison, Mazdutide is still confined to clinical trials, meaning it’s not yet available to the public. Pricing is an important factor, Tirzepatide can cost between $800 and $1,200 per month, and insurance coverage may vary.

Although the cost of Mazdutide has not been released, it’s likely to be high, given the pattern seen with new drugs. This sets up an interesting situation: Tirzepatide’s established presence in the market offers immediate access, but if Mazdutide’s price is more affordable when it’s released, it could become a formidable alternative.

Which One Is Better?

When comparing treatments for weight loss, a few factors help determine which one is more effective. We need to observe safety, accessibility, and overall impact on daily life. Here’s a look at how Tirzepatide and Mazdutide stack up:

• Effectiveness: Tirzepatide leads the way, achieving up to 20.2% weight loss in clinical studies. Mazdutide, which is still being studied, has shown up to 15% weight loss so far. [2] [3]
• Safety: Both medications have similar side effects, though Tirzepatide has been tested more thoroughly in real-world use. [5]
• Accessibility: Tirzepatide is FDA-approved and widely available, while Mazdutide remains in clinical trials.

Conclusion

Mazdutide and tirzepatide represent significant advancements in obesity and type 2 diabetes management, leveraging GLP-1-based mechanisms to achieve weight loss and glycaemic control. Tirzepatide currently leads with higher weight loss percentages and extensive clinical data, while mazdutide shows promise as a dual GLP-1 and glucagon agonist with strong phase II results.

Ongoing phase III trials for mazdutide will shape the future of these therapies. Both drugs offer hope for improving health outcomes in obesity and type 2 diabetes, with distinct mechanisms that cater to diverse patient needs.

FAQ

What’s the difference between Mazdutide and Tirzepatide?

Mazdutide and Tirzepatide are both newer obesity treatments being studied for their effects on weight loss. Tirzepatide, also known as Mounjaro, is already approved and available, while Mazdutide is still in the clinical trial phase.

Which is better for weight loss: Tirzepatide, Mazdutide, Dulaglutide or Semaglutide?

Mazdutide outperformed Trulicity (which contains Dulaglutide) in trials, showing better weight loss results compared to this commonly prescribed GLP-1 agonist. While Dulaglutide helps with weight loss, Semaglutide and Tirzepatide have demonstrated superior weight loss effects. Many studies suggest that Tirzepatide, a dual GIP/GLP-1 receptor agonist, is the most effective among these options for weight reduction.

Are there other treatments being investigated?

Yes, Retatrutide is another investigational treatment for obesity currently being researched. It’s being studied to see if it can deliver weight loss effects similar to or better than those of Tirzepatide and Mazdutide.

What is Retatrutide and how does it compare to Mazdutide and Tirzepatide?

Retatrutide is another obesity treatment being studied for weight loss potential. Like Tirzepatide and Mazdutide, it acts on the same gut hormone pathways, but early trials suggest it might have even greater weight loss effects than the other two. However, Retatrutide is still in the research phase and is not approved for general use.